An Insider At Giant Biogene Holding Lowered Their Holding Recently
An Insider At Giant Biogene Holding Lowered Their Holding Recently
Insiders were net sellers of Giant Biogene Holding Co., Ltd.'s (HKG:2367 ) stock during the past year. That is, insiders sold more stock than they bought.
過去一年中，內部人士淨賣出了鉅子生物(臨時代碼)(HKG:2367)的股票。也就是說，內部人士賣出的股票比購買的股票多。
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
儘管在長期投資中內部交易並不是最重要的事情，但從邏輯上講，您應該關注內部人員是否買入或出售股票。
The Last 12 Months Of Insider Transactions At Giant Biogene Holding
在鉅子生物(臨時代碼)進行了最近12個月的內部交易中，我們可以看到最大的內部人士銷售情況是由首席科學家樊代迪（Daidi Fan）進行的，價值16億港元的股票，每股價格約爲49.40港元。因此，我們知道內部人員以每股46.70港元左右的股價出售了股票。我們通常不喜歡看到內部人員出售，但銷售價格越低，它對我們的擔憂就越大。我們注意到這次銷售是在當前價格左右進行的，因此這不是一個主要的問題，儘管它並不是一個好兆頭。過去一年中唯一一個出售內部股票的個人是樊代迪。值得注意的是，樊代迪還是最大的買家之一，購買了價值16億港元的股票。
Over the last year, we can see that the biggest insider sale was by the Chief Scientific Officer, Daidi Fan, for HK$1.6b worth of shares, at about HK$49.40 per share. So we know that an insider sold shares at around the present share price of HK$46.70. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign. The only individual insider seller over the last year was Daidi Fan. Notably Daidi Fan was also the biggest buyer, having purchased HK$1.6b worth of shares.
SEHK:2367 2024年6月20日內部交易成交量。在過去的季度中，內部人士累計賣出了16億港元的股票。但這僅比16億港元的買入稍微多了一些。總體上看，我們認爲這次最近的交易並沒有爲我們揭示內部人員作爲一組對公司前景的看法提供太多的信息。
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
你可以在下面看到內部人士在過去12個月的交易（按公司和個人分類）的可視化描述。點擊下面的圖表，您可以看到每個內部交易的詳細信息！
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
如果您和我一樣，您就不會錯過這個免費的小盤股票列表，這些股票不僅被內部人士購買，而且估值也很有吸引力。
Are Giant Biogene Holding Insiders Buying Or Selling?
在過去的季度中，內部人士累計賣出了16億港元的股票。但這僅比16億港元的買入稍微多了一些。總體上看，我們認爲這次最近的交易並沒有爲我們揭示內部人員作爲一組對公司前景的看法提供太多的信息。
In the last quarter there were insider sales totalling HK$1.6b. But that was only a smidgen more than the HK$1.6b worth of buying. Looking at the net result, we don't think this recent trading sheds much light on how insiders, as a group, are feeling about the company's prospects.
在過去的季度中，內部人士累計賣出了16億港元的股票。但這僅比16億港元的買入稍微多了一些。總體上看，我們認爲這次最近的交易並沒有爲我們揭示內部人員作爲一組對公司前景的看法提供太多的信息。
Insider Ownership Of Giant Biogene Holding
鉅子生物(臨時代碼)內部人士持股情況
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Giant Biogene Holding insiders own about HK$27b worth of shares (which is 58% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
查看公司內部人士的總持股量可以幫助了解他們與普通股東是否保持良好的一致性。通常情況下，內部人持股比例越高，他們就越有動力爲長期發展建設公司。鉅子生物的內部人士擁有大約27億港元的股票份額（佔公司的58%）。我喜歡看到這種程度的內部人士持股，因爲這增加了管理層考慮股東最佳利益的機會。
So What Do The Giant Biogene Holding Insider Transactions Indicate?
鉅子生物(臨時代碼)內部交易的具體意義是什麼？
We can't make any useful conclusions about recent trading, since insider buying and selling has been balanced. It's great to see high levels of insider ownership, but looking back over the last year, we'd need to see more buying to gain confidence from the Giant Biogene Holding insider transactions. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 2 warning signs for Giant Biogene Holding you should know about.
我們無法得出有關最近交易的有用結論，因爲內部買賣已達到平衡。看到高水平的內部人士持股是有益的，但回顧過去一年，我們需要看到更多的買入才能從鉅子生物(臨時代碼)的內部交易中獲得信心。因此，雖然知道內部人士正在進行購買或銷售是有幫助的，但了解特定公司面臨的風險也是有益的。每個公司都面臨風險，我們發現了2個關於鉅子生物(臨時代碼)的警示信號，你應該知道。
Of course Giant Biogene Holding may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然，鉅子生物(臨時代碼)並不是最好的股票可供買入。因此，您可能希望查看這個免費的高質量公司收集。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。